Review of hepatitis B therapeutics

Clinical Infectious Diseases

Volumn 51, Issue 10, 2010, Pages 1201-1208

  Bhattacharya, Debika ^a   Thio, Chloe L ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; ALPHA INTERFERON; ATAZANAVIR; DIDANOSINE; EMTRICITABINE; ENTECAVIR; LAMIVUDINE; NUCLEOSIDE ANALOG; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; PLACEBO; RIBAVIRIN; TELBIVUDINE; TENOFOVIR; TENOFOVIR DISOPROXIL;

ALOPECIA; ANOREXIA; ARTHRALGIA; BONE DENSITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DEPRESSION; DIARRHEA; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG FEVER; DRUG FORMULATION; DRUG HALF LIFE; DRUG INDICATION; DRUG POTENCY; DRUG TARGETING; FANCONI RENOTUBULAR SYNDROME; FATIGUE; FATTY LIVER; HEADACHE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTHYROIDISM; HYPOTHYROIDISM; INSOMNIA; IRRITABILITY; KIDNEY TUBULE DISORDER; LACTIC ACIDOSIS; LIFE CYCLE; MIXED INFECTION; MYALGIA; MYOPATHY; NONHUMAN; PERIPHERAL NEUROPATHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; TREATMENT DURATION;

ANTIVIRAL AGENTS; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; INTERFERON TYPE I, RECOMBINANT; NUCLEOSIDES;

EID: 78349236621     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/656624     Document Type: Review

References (61)

1. Dienstag JL. Hepatitis B virus infection. N Engl J Med 2008; 359:1486-1500.
2. Urban S, Schulze A, Dandri M, Petersen J. The replication cycle of hepatitis B virus. J Hepatol 2010; 52:282-284.
3. Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 2005; 5:215-229.
4. Darnell JE, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994; 264:1415-1421.
5. Pegasys [package insert]. Nutley, NJ: Hoffmann-La Roche, 2002.
6. Cooksley WGE, Piratvisuth T, Lee S-D, et al. Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat 2003; 10:298-305.
7. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50:661-662.
8. Emtriva [package insert]. Foster City, CA: Gilead Sciences, 2003.
9. Epivir-HBV [package insert]. Research Triangle Park, NC: GlaxoSmith- Kline, 1998.
10. Tyzeka [package insert]. East Hanover, NJ: Novartis, 2006.
11. Lin K, Karwowska S, Lam E, Limoli K, Evans TG, Avila C. Telbivudine exhibits no inhibitory activity against HIV-1 clinical isolates in vitro. Antimicrob Agents Chemother 2010; 54:2670-2673.
12. Milazzo L, Caramma I, Lai A, et al. Telbivudine in the treatment of chronic hepatitis B: experience in HIV type-1-infected patients naive for antiretroviral therapy. Antivir Ther 2009; 14:869-872.
13. Lai CL, Chien RN, Leung NW, et al; Asia Hepatitis Lamivudine Study Group. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998; 339:61-68.
14. Gish RG, Trinh H, Leung N, et al. Safety and antiviral activity of emtricitabine (FTC) for the treatment of chronic hepatitis B infection: a two-year study. J Hepatol 2005; 43:60-66. (Pubitemid 40805273)
15. Lai C-L, Gane E, Liaw Y-F, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007; 357:2576-2588.
16. Hepsera [package insert]. Foster City, CA: Gilead Sciences, 2002.
17. Viread [package insert]. Foster City, CA: Gilead Sciences, 2009.
18. Fisher EJ, Chaloner K, Cohn DL, et al. The safety and efficacy of adefovir dipivoxil in patients with advanced HIV disease: a randomized, placebo-controlled trial. AIDS 2001; 15:1695-1700. (Pubitemid 32918124)
19. Tanji N, Tanji K, Kambham N, Markowitz GS, Bell A, D'agati VD. Adefovir nephrotoxicity: possible role of mitochondrial DNA depletion. Hum Pathol 2001; 32:734-740.
20. Marcellin P, Chang T-T, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003; 348:808-816. (Pubitemid 36245757)
21. Ha NB, Garcia RT, Trinh HN, et al. Renal dysfunction in chronic hepatitis B patients treated with adefovir dipivoxil. Hepatology 2009; 50:727-734.
22. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med 2005; 352:2673-2681. (Pubitemid 41007822)
23. Delaney WE, Ray AS, Yang H, et al. Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus. Antimicrob Agents Chemother 2006; 50:2471-2477. (Pubitemid 43993188)
24. Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008; 359:2442-2455.
25. Baraclude [package insert]. Princeton, NJ: Bristol-Myers Squibb, 2005.
26. Levine SHD, Yamanaka G, Zhang S, Rose R, Weinheimer S, Colonno RJ. Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro. Antimicrob Agents Chemother 2002; 46:2525-2532. (Pubitemid 34793459)
27. Lange CM, Bojunga J, Hofmann WP, et al. Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function. Hepatology 2009; 50:2001-2006.
28. Lai C-L, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006; 354:1011-1020. (Pubitemid 43357805)
29. Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354:1001-1010. (Pubitemid 43357804)
30. McMahon MA, Jilek BL, Brennan TP, et al. The HBV drug entecavir - effects on HIV-1 replication and resistance. N Engl J Med 2007; 356: 2614-2621.
31. Allen MI, Deslauriers M, Andrews CW, et al; Lamivudine Clinical Investigation Group. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Hepatology 1998; 27:1670-1677.
32. Tenney DJ, Levine SM, Rose RE, et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine. Antimicrob Agents Chemother 2004; 48:3498-3507.
33. Lok ASF, Lai C-L, Leung N, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003; 125: 1714-1722. (Pubitemid 37500436)
34. Benhamou Y, Bochet M, Thibault V, et al. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology 1999; 30:1302-1306. (Pubitemid 29510871)
35. Gish RG, Trinh H, Leung N, et al. Safety and antiviral activity of emtricitabine (FTC) for the treatment of chronic hepatitis B infection: a two-year study. J Hepatol 2005; 43:60-66. (Pubitemid 40805273)
36. Liaw Y-F, Gane E, Leung N, et al. 2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009; 136:486-495.
37. Fu L, Cheng YC. Role of additional mutations outside the YMDD motif of hepatitis B virus polymerase in L(-)SddC (3TC) resistance. Biochem Pharmacol 1998; 55:1567-1572. (Pubitemid 28223448)
38. Sheldon J, Ramos B, Garcia-Samaniego J, et al. Selection of hepatitis B virus (HBV) vaccine escape mutants in HBV-infected and HBV/ HIV-coinfected patients failing antiretroviral drugs with anti-HBV activity. J Acquir Immune Defic Syndr 2007; 46:279-282. (Pubitemid 350287353)
39. Marcellin P, Chang T-T, Lim SGL, et al. Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2008; 48:750-758.
40. Sheldon J, Camino N, Rodés B, et al. Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. Antivir Ther 2005; 10:727-734. (Pubitemid 41376852)
41. Fung SMT, Sherman M, Popovic V. Tenofovir (TDF) is effective in lamivudine (LAM)-resistant chronic hepatitis B patients who harbour rtA194T at baseline. In: Program and abstracts of the 60th Annual Meeting of the American Association for the Study of Liver Diseases. 2009. Poster 399.
42. Tenney DJ, Rose RE, Baldick CJ, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy. Hepatology 2009; 49:1503-1514.
43. Chang T-T, Lai C-L, Kew Yoon S, et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010; 51:422-430.
44. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents: December 1, 2009. Department of Health and Human Services, 2009:1-168. http://www.aidsinfo.nih.gov/ContentFiles/Adult andAdolescentGL.pdf. Accessed 27 September 2010.
45. Di Martino V, Thevenot T, Colin J-F, et al. Influence of HIV infection on the response to interferon therapy and the long-term outcome of chronic hepatitis B. Gastroenterology 2002; 123:1812-1822. (Pubitemid 35408305)
46. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009; 50: 227-242.
47. Keeffe EB, Dieterich DT, Han SH, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol 2008; 6:1315-1341.
48. Sung JJY, Lai J-Y, Zeuzem S, et al. Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B. J Hepatol 2008; 48:728-735.
49. Hui C-K, Zhang H-Y, Bowden S, et al. 96 weeks combination of adefovir dipivoxil plus emtricitabine vs. adefovir dipivoxil monotherapy in the treatment of chronic hepatitis B. J Hepatol 2008; 48:714-720.
50. Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352:2682-2695. (Pubitemid 41007823)
51. Lai C-L, Leung N, Teo E-K, et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 2005; 129:528-536. (Pubitemid 41096641)
52. Matthews GV, Avihingsanon A, Lewin SR, et al. A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individuals in Thailand. Hepatology 2008; 48:1062-1069.
53. Dore GJ, Cooper DA, Pozniak AL, et al. Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy - naive and - experienced patients co-infected with HIV-1 and hepatitis B virus. J Infect Dis 2004; 189:1185-1192. (Pubitemid 38457242)
54. Rockstroh JK, Bhagani S, Benhamou Y, et al. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. HIV Med 2008; 9:82-88.
55. Soriano V, Puoti M, Peters M, et al. Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV-Hepatitis B Virus International Panel. AIDS 2008; 22:1399-1410.
56. Lok A. Overview of the management of chronic hepatitis B and case examples. In: UpToDate. Basow DS, ed. Waltham, MA: UpToDate, 2010.
57. Yatsuji H, Suzuki F, Sezaki H, et al. Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two-year follow-up. J Hepatol 2008; 48:923-931.
58. Rapti I, Dimou E, Mitsoula P, Hadziyannis SJ. Adding-on versus switching- to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology 2007; 45:307-313.
59. van Bömmel F, Zöllner B, Sarrazin C, et al. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatology 2006; 44:318-325. (Pubitemid 44214870)
60. Schildgen O, Sirma H, Funk A, et al. Variant of hepatitis B virus with primary resistance to adefovir. N Engl J Med 2006; 354:1807-1812. (Pubitemid 44079361)
61. Fung SK, Wong F, Hussain M, Lok AS. Sustained response after a 2- year course of lamivudine treatment of hepatitis B e antigen-negative chronic hepatitis B. J Viral Hepat 2004; 11:432-438. (Pubitemid 39336224)